ArticleDrugs & aging2026
Long-Term Proton Pump Inhibitor Therapy Is Common Among Older Adults: An 8-Year Finnish Nationwide Register Study.
Article in Drugs & aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundProton pump inhibitors (PPIs) are widely prescribed for acid-related gastrointestinal conditions, yet concerns persist regarding their long-term use, particularly among older adults, due to potential adverse effects and frequent lack of clear indications. This study examined nationwide trends and patterns of PPI use in Finland, with a specific focus on long-term use among older adults.
methodsWe used nationwide prescription data from the Finnish Prescription Centre (2017-2024) to examine PPI use in older adults (aged ≥ 65 years), with working-age adults (aged 18-64 years) as a comparison group. Patterns of PPI use, initiation, long-term use (≥ 3 dispensations/year), polypharmacy, and co-medication with antithrombotic agents, corticosteroids, and nonsteroidal antiinflammatory drugs were analyzed using descriptive statistics.
resultsBetween 2017 and 2024, the number of PPI users increased by 12% and dispensations by 37%, with a steeper increase among older than working-age adults. In 2024, nearly half of all PPI users were aged ≥ 65 years, of whom 56.3% were classified as long-term users, compared with 34.1% among working-age adults. Long-term PPI use increased in both age groups, with an approximately 2.5-fold higher relative annual increase among older adults than among working-age adults. Long-term PPI use was more common among female than male individuals across nearly all age groups. Among older adults, PPI use was frequently accompanied by polypharmacy: 47% used more than ten other prescription medicines, and 39% received anticoagulants.
conclusionsLong-term PPI use is highly prevalent among older adults in Finland. These findings highlight the need for regular medication reviews and targeted deprescribing efforts to improve pharmacotherapy quality and safety in aging populations.
Identifiers
42814388What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.